# Surgical Staging in Locally Advanced Cervical Cancer: Precision, Risks, and the ‘Helmet’ Analogy

## TL;DR

Surgical staging is more accurate than scans for detecting cervical cancer spread to lymph nodes, but should be used selectively in high-risk patients with proper imaging and biomarkers.

## Contribution

The paper proposes a pragmatic pathway integrating selective surgery, advanced imaging, and biomarkers for cervical cancer staging.

## Key findings

- Surgical staging detects ~21% more occult para-aortic metastases in pelvic-positive patients.
- PET/CT has poor sensitivity for small nodal disease (<5 mm), while surgical staging modifies radiotherapy planning in ~18% of cases.
- Minimally invasive staging is feasible with low morbidity in expert centers, but real-world outcomes may vary.

## Abstract

Locally advanced cervical cancer often spreads to lymph nodes near the aorta (para-aortic nodes). Today, PET/CT scans are the standard way to look for this spread, but they frequently miss very small deposits. Surgeons can remove and examine these nodes (surgical staging), which is the most accurate method to uncover hidden disease. However, operating on everyone is not always necessary or practical, and surgery must not delay the start of chemoradiation. This review explains when surgical staging may help—mainly in carefully selected, higher-risk patients—by guiding whether to extend radiation fields or adjust systemic therapy. We summarize the best available studies, including one randomized trial, large databases, and ongoing prospective trials. We also discuss new tools that could sharpen selection and reduce morbidity, such as sentinel node mapping, molecular assays (e.g., OSNA), and blood-based HPV-DNA biomarkers. Overall, we propose a pragmatic, quality-assured pathway led by accredited centers: combine advanced imaging, selective surgery, and biomarkers so that the patients most likely to benefit are the ones who receive surgical staging.

Background/Objectives: This study aims to critically appraise the role of para-aortic surgical staging in locally advanced cervical cancer (LACC) in the era of advanced imaging, and to outline how selective surgery and biomarkers could be integrated within modern, quality-assured treatment pathways. Methods: Narrative review of randomized trials, large databases, and prospective/retrospective series comparing para-aortic lymphadenectomy with imaging-based staging; focused appraisal of Uterus-11, NCDB analyses, and ongoing prospective trials (PAROLA with Senti-PAROLA as one of its sub-studies and PALDISC). Emerging technologies (PET/MRI, radiomics/AI) and molecular assays (OSNA, HPV-ctDNA) were also assessed. Results: PET/CT remains the standard for distant staging, but sensitivity for low-volume nodal disease (<5 mm) is poor; in pelvic-positive/para-aortic-negative patients, occult para-aortic metastases approach ~21%. Para-aortic surgical staging modifies radiotherapy planning in ~18% of cases and can act as a de-escalation tool by avoiding unnecessary extended-field CRT (EF-CRT) when para-aortic nodes are negative. Uterus-11 showed no overall survival difference versus CT-based staging, but suggested benefit in FIGO 2009 stage IIB; its design (CT comparator, optimistic assumptions, limited power) constrains inference. Minimally invasive extraperitoneal/transperitoneal staging is feasible with low morbidity in expert centers, yet real-world management may worsen outcomes. The role of systemic intensification in node-positive disease remains undefined: PALN-positive patients were excluded from the INTERLACE trial. In the KEYNOTE-826 study, subgroup analyses according to nodal status were not reported, although the benefit of pembrolizumab remained consistent irrespective of bevacizumab use. Sentinel para-aortic mapping and biomarkers (e.g., HPV-ctDNA) may refine selection and reduce morbidity. Conclusions: Surgical staging is the most accurate method to detect occult para-aortic disease. Its routine use is not justified, but it may benefit selected high-risk patients, particularly where decisions on EF-CRT or systemic therapy hinge on para-aortic status. Future practice should integrate advanced imaging, selective surgery, and biomarkers within accredited centers, guided by large collaborative trials conducted under international quality frameworks such as ESGO/ESTRO/ESP guidelines.